Aptorum-backed DiamiR expands Alzheimer’s diagnostic efforts

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

AlzLabs collaboration comes as Aptorum and DiamiR prepare to become Niki BioSolutions, raising questions about future of brain diagnostics.

Alzheimer’s disease develops silently over many years, yet confirming what’s happening inside the brain often requires some of medicine’s most expensive and least accessible tools. Amyloid PET scans, which can reveal hallmark Alzheimer’s pathology, remain the gold standard. They are also costly, highly specialized and unavailable to large parts of the population.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE